Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05851391 · ClinicalTrials.gov registry record · Phase 2
buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest
A Phase 2 study of Seizures and Status Epilepticus, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05851391 is a Phase 2 study of Seizures and Status Epilepticus that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 30 participants, below the 934-participant average among 39 other Seizures trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05851391, a Phase 2 study of Seizures and Status Epilepticus, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
RESTORE is a randomized clinical trial investigating the safety and feasibility of using EEG treatment targets (burst suppression vs. seizure suppression) for post-cardiac arrest refractory status epilepticus treatment.
Conditions Studied
Interventions
- DRUG Burst Suppression EEG Target Intravenous Anesthesia
- DRUG Seizure Suppression EEG Target Intravenous Anesthesia
Study Locations (1)
California
- Zuckerberg San Francisco General Hospital - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-08-07 |
| Est. Completion | 2027-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05851391
The ClinicalTrials.gov registry entry for NCT05851391 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 934-participant average among 39 other Seizures trials with a reported enrollment target (97% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Seizures appearing as the primary indexed condition, and to 2 interventions - of which Burst Suppression EEG Target Intravenous Anesthesia is the first listed.
NCT05851391 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05851391 about?
NCT05851391 is a clinical study titled "buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest". RESTORE is a randomized clinical trial investigating the safety and feasibility of using EEG treatment targets (burst suppression vs. seizure suppression) for post-cardiac arrest refractory status epilepticus treatment.
What is the current status of trial NCT05851391?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2023-08-07. Estimated completion is 2027-04-30.
What conditions does trial NCT05851391 study?
This clinical trial studies the following conditions: Seizures, Status Epilepticus, Heart Arrest, Hypoxia-Ischemia, Brain, Refractory Status Epilepticus.
What interventions are being tested in trial NCT05851391?
The interventions under investigation include: Burst Suppression EEG Target Intravenous Anesthesia (DRUG), Seizure Suppression EEG Target Intravenous Anesthesia (DRUG).
Who is sponsoring clinical trial NCT05851391?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05851391 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Seizures
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest
RECRUITING · Phase 2
-
Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases
RECRUITING · Phase 2
-
RNS System LGS Feasibility Study
ACTIVE NOT RECRUITING · Phase 2
-
Hypovitaminosis D in Neurocritical Patients
COMPLETED · Phase 2
-
Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency
COMPLETED · Phase 2
-
Intranasal Midazolam Versus Rectal Diazepam for Treatment of Seizures
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.